Videos

- Career builder (2)
- Events (4)
- FDA (14)
- Interviews (6)
- Pharmacists (4)
- Technology (6)

Pharma Jobs

- Qualty Control and Quality Assurance Jobs (210)
- Administration Jobs (94)
- Clinical Jobs (116)
- Formulation and Process Development jobs (102)
- H R Jobs (63)
- Manufacturing or Production Jobs (92)
- Packaging Jobs (15)
- Pharma Engineering Jobs (137)
- Pharma IT Jobs (28)
- Pharmaceutical Marketing Jobs (54)
- Pharmaceutical sales jobs (470)
- Project Management Jobs (126)
- Regulatory Affairs Jobs (33)
- Research and Development jobs (405)
- Validation Jobs (30)
- Accounting and Finance Jobs (127)

Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals

in

Manufacturing Articles

Transgenic milk production offers a cost-effective system for the manufacturing of large amounts of complex proteins. Specifically, commercialization is near for recombinant human antithrombin (rhAT) expressed in transgenic dairy goats. The product received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicine Agency.

This article reviews the reasons why transgenic milk is a cost-effective system. Also reviewed is the earlier research on targeting heterologous proteins to the mammary glands of many different animals. The final section describes the process by which goats express rhAT in their milk at approximately 2 g/L. The human AT purified from milk is structurally indistinguishable from human plasma–derived AT with the exception of carbohydrates. Clinical studies are ongoing on the prevention of deep-vein thrombosis.

View Full Article

Author(s):

Yann Echelard , Carol A. Ziomek , Harry M. Meade.

Journal:

BioPharm International, August 2006.

Copyright:

Login or register to post comments

Review Articles:

Please see Instruction
For Authors and Copyright Agreement Form

Pharma News:

Please email us your news, announcement or info to news @ pharmainfo.net

Pharma Blogs

Canadians will have easier access to plan B

Submitted by sailajabyrisetty on Sat, 07/12/2008 - 15:27.

in

MyBlog

A new National Drug Schedule change will move single-dose 'plan B' (levonorgestrel), an emergency contraceptive pill, to Schedule III from Schedule II. This means that now pharmacies may choose to move it from behind the counter to the same pharmacy self-selection area where otehr Schedule III medicines are sold. Changes to the National Schedules are automatically adopted by some provinces like Ontario, New Brunswick, Manitoba, Alberta... some provinces and territories will decide on their own thether or not to adopt the scheduling change. Women's group want plan B more accessible. They argue that consulation fees and personal questions by pharmacists are a barrier to patients getting the emergency contraceptive pill. However, some pharmacy groups don't like the change. They say pharmacists offer valuable services, such as determining when Plan B is not appropriate...and counselling on birth control and sexually transmitted infections.